Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cumberland Pharmaceuticals Inc CPIX

Healthcare
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. Its portfolio of brands includes Acetadote injection, for the treatment of acetaminophen poisoning; Caldolor injection, for the treatment of pain and fever, Kristalose for oral solution, a... see more

Recent & Breaking News (NDAQ:CPIX)

Cumberland Pharmaceuticals Reports Second Quarter 2014 Financial Results

PR Newswire August 5, 2014

Cumberland Pharmaceuticals To Announce Second Quarter 2014 Financial Results On August 5, 2014

PR Newswire July 22, 2014

Cumberland Pharmaceuticals Reports First Quarter 2014 Financial Results

PR Newswire May 13, 2014

Cumberland Pharmaceuticals Launches Vaprisol® Promotion

PR Newswire May 7, 2014

Cumberland Pharmaceuticals And Gloria Pharmaceuticals Announce Joint Research & Development Investment

PR Newswire May 6, 2014

Cumberland Pharmaceuticals To Announce First Quarter 2014 Financial Results On May 13, 2014

PR Newswire April 29, 2014

Caldolor® Pediatric Pain Study Results To Be Presented At The Pediatric Anesthesiology 2014 Conference

PR Newswire March 7, 2014

Cumberland Pharmaceuticals Reports 2013 Fourth Quarter And Annual Financial Results

PR Newswire March 4, 2014

Cumberland Pharmaceuticals Acquires Vaprisol® from Astellas Pharma US, Inc.

PR Newswire March 3, 2014

Cumberland Pharmaceuticals To Announce 2013 Year-End Financial Results On March 4, 2014

PR Newswire February 27, 2014

Cumberland Pharmaceuticals To Announce Third Quarter 2013 Financial Results On November 5, 2013

PR Newswire October 29, 2013

Cumberland Pharmaceuticals And Pernix Therapeutics Enter Into Exclusive Agreement To Promote Omeclamox-Pak®

PR Newswire October 28, 2013

Caldolor® Studies to be Presented at the Annual Meeting of the American Society of Anesthesiologists

PR Newswire October 10, 2013

Cumberland Pharmaceuticals Reports Second Quarter Financial Results

PR Newswire August 6, 2013

Cumberland Pharmaceuticals To Announce Second Quarter 2013 Financial Results On August 6, 2013

PR Newswire July 29, 2013

Cumberland Pharmaceuticals Reports FDA Approval For Updated Acetadote® Labeling

PR Newswire June 10, 2013

EmergingGrowth.com looks at Merus Labs International Inc. After Better than Expected Q2

Accesswire May 28, 2013

Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York

PR Newswire May 15, 2013

EmergingGrowth.com looks at Small Cap Specialty Pharmaceutical Plays

Accesswire May 14, 2013

Cumberland Pharmaceuticals Reports First Quarter Financial Results

PR Newswire May 2, 2013